Health Care • Biotechnology: Pharmaceutical Preparations
$4.01 ▼ -0.03
(-0.74%)
MKT CAP: $760.2M • VOL: 3.29M
52W L $3 52W H $7
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
ANNX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$216.4M | -$154.1M | -$143.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$206.7M | -$138.2M | -$134.2M |
| EBITDA (Normalized) | -$216.3M | -$154.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$186.4M | -$118.0M | -$121.1M |
| Capital Expenditures (CapEx) | $137.0K | $15.0K | — |
| Free Cash Flow (FCF) | -$186.5M | -$118.0M | -$121.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $162.1M | $49.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $211.6M | $293.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANNX.